



Dedicated To Life

September 15, 2025

BSE Limited

1st Floor,
P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Code: Zyduslife

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of two press releases, both dated September 15, 2025, with following titles:

1. ZyVet® Launches First Generic Treatment for Canine Urinary Incontinence and
2. ZyVet® launches affordable Furosemide tablets to support long-term heart care trusted diuretic for dogs and cats now available in a generic form

The contents of the press releases give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,

For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI

COMPANY SECRETARY AND COMPLIANCE OFFICER

MEMBERSHIP NO. FCS7063

Encl.: As above

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



ZyVet® Launches First Generic Treatment for Canine Urinary Incontinence *Cost-Effective Relief for Aging Dogs and Concerned Pet Owners*

Pennington, NJ – September 15, 2025

ZyVet® Animal Health, a leader in affordable generic pharmaceuticals for animals, a wholly owned subsidiary of Zydus Pharmaceuticals (USA) Inc., itself a wholly owned subsidiary of Zydus Lifesciences Ltd., a global innovation led healthcare company, has released the first FDA-approved generic of phenylpropranolamine hydrochloride tablets, a trusted treatment for managing urinary incontinence in dogs. This latest product underscores ZyVet’s mission to bring trusted, high-quality, and cost-effective therapies to veterinary professionals across the United States.

Phenylpropranolamine hydrochloride is commonly prescribed to treat urinary incontinence in dogs due to urethral sphincter hypotonus. Often seen in spayed females and aging dogs, urethral sphincter hypotonus can lead to frustrating and embarrassing accidents. ZyVet’s generic provides dependable symptom relief while supporting stronger long-term client compliance. Available in multiple strengths to support precise dosing, the product is designed with the needs of both veterinary teams and pet owners in mind.

Speaking on this development, Punit Patel, President and CEO, Zydus Americas, said “Urinary incontinence affects quality of life for both pets and their families. Our phenylpropranolamine hydrochloride tablets deliver on both clinical reliability and affordability, enabling veterinarians to confidently treat more patients and maintain client compliance. We’re proud to offer an option that removes cost as a barrier to compassionate care. With each launch, we reinforce that innovation doesn’t need to come with a premium price tag – and that every pet should have access to high-quality treatment options.”

ZyVet’s rapid portfolio expansion leads a paradigm shift in the industry reinforcing that generic animal health products are as effective as the pioneer brands. As a division of Zydus Lifesciences, ZyVet benefits from more than 70 years of pharmaceutical, R&D, Regulatory, QA/QC, manufacturing scale, excellence and expertise.

Today, fewer than 20% of FDA-approved animal drugs have a generic version, highlighting the continued need for affordable veterinary therapies¹. With the launch of phenylpropranolamine hydrochloride tablets, ZyVet reinforces its role as a leader in the underserved generics space – bringing affordable innovation to animal care and making essential treatments more accessible for everyday pet owners and their veterinarians.

1. GADA, Generic Animal Drug Alliance; Information for Pet Owners & Consumer
<https://www.gadaonline.org/animalgenerics/facts.cfm>

Important Safety Information:

Phenylpropranolamine Hydrochloride is a sympathomimetic amine, closely related to ephedrine, used to manage urinary incontinence in dogs caused by urethral sphincter hypotonus. Possible side effects include vomiting, hypertension, anorexia, weight loss, proteinuria, and behavioral changes such as anxiety and aggression. Rare but serious reactions may include seizures, tremors, renal failure, elevated liver enzymes, and heart arrhythmias. Use with caution in dogs with pre-existing heart conditions, and note that its safety in pregnant, lactating, or breeding dogs has not been established.

Regular veterinary monitoring is crucial to minimize risks. If your dog shows any unusual symptoms, contact your veterinarian immediately.



CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

For more safety information, please refer to the Phenylpropanolamine Hydrochloride [full Prescribing Information](#).
Approved by FDA under ANADA # 200-787

About ZyVet Animal Health

Founded in 2019 and headquartered in Pennington, New Jersey, **ZyVet® Animal Health** is dedicated to providing high-quality generic medications for companion animals. A wholly-owned division of **Zydus Lifesciences**, one of the world's largest generics manufacturers, ZyVet leverages a global legacy of pharmaceutical excellence to serve the veterinary community with accessible, reliable treatment options. Visit **ZyVetUSA.com** to learn more about ZyVet's expanding portfolio of affordable solutions for today's veterinary practice.

About Zydus Lifesciences

Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 28,000 people worldwide, including 1,500 scientists engaged in R&D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. For more details visit www.zyduslife.com

Contact Information

Courtney Carney, Marketing & Communications
ccarney@zydususa.com
Phone: (682) 552-4520

ZyVet® launches affordable Furosemide tablets to support long-term heart care trusted diuretic for dogs and cats now available in a generic form

Pennington, NJ – September 15, 2025

ZyVet® Animal Health, a leader in affordable generic pharmaceuticals for animals and a wholly owned subsidiary of Zydus Pharmaceuticals (USA) Inc., itself a wholly owned subsidiary of Zydus Lifesciences Ltd., a global innovation led healthcare company, announces the launch of first veterinary approved generic of Furosemide Tablets, a critical therapy for managing congestive heart failure and chronic fluid retention in dogs and cats.

Furosemide remains the most widely used veterinary diuretic for reducing edema and pulmonary congestion due to cardiac, renal, or systemic disease. ZyVet's formulation offers veterinarians a consistent, cost-effective solution that supports long-term therapy, without compromising dosing flexibility or product availability.

Speaking on this development, Punit Patel, President and CEO, Zydus Americas, said, "We are happy to participate in the animal health segment and launch the first approved generic of Furosemide in the US. Managing chronic conditions in pets is a long journey, and consistency in care makes all the difference. At ZyVet, we believe in ensuring that veterinarians and pet owners have reliable, affordable options they can count on, and this launch is another step toward making quality drugs accessible to all."

"Heart failure and chronic fluid retention require lifelong management, and that often means long-term medication," said Punit Patel. "By offering Furosemide as part of our trusted portfolio, we're helping veterinary teams maintain continuity of care while supporting client adherence. Our goal is to make innovation affordable and ensure veterinarians and pet owners have high-quality products they can count on, without cost or supply concerns that too often disrupt care. ZyVet was launched with the belief that veterinarians and pet owners shouldn't have to choose between cost and care. Our Furosemide tablets are another step toward making clinical innovation affordable."

Manufactured under stringent quality standards, ZyVet's Furosemide tablets are available in multiple strengths to accommodate patient-specific dosing. As with all ZyVet products, the new formulation reflects the company's commitment to providing veterinarians and pet owners with much needed alternatives to higher-cost pioneer drugs.

ZyVet's expanding product portfolio supports a growing paradigm shift in the veterinary pharmaceutical market, where access to generic options remains limited despite increasing demand. Fewer than 20% of products in animal health have generic equivalents – yet the need for affordable, high-quality products is growing¹.

With Furosemide, ZyVet launches another first to market veterinary generic pharmaceutical and strengthens its rapidly growing presence in the animal health pharmaceutical market. As the dedicated animal health division of Zydus Lifesciences, ZyVet benefits from more than 70 years of pharmaceutical R&D, Regulatory, QA/QC, and Manufacturing scale, excellence and expertise.

1. GADA, Generic Animal Drug Alliance; Information for Pet Owners & Consumer <https://www.gadaonline.org/animalgenerics/facts.cfm>

Important Safety Information:

Furosemide Tablets is a highly effective diuretic and if given in excessive amounts as with any diuretic may lead to excessive diuresis which could result in electrolyte imbalance, dehydration and reduction of plasma volume enhancing the risk of circulatory collapse, thrombosis, and embolism. Therefore, the animal should be observed for early signs of fluid depletion with electrolyte imbalance, and corrective measures administered. Excessive loss of potassium in patients receiving digitalis or its glycosides may precipitate digitalis toxicity. Caution should be exercised in animals administered potassium-depleting steroids. It is important to correct potassium deficiency with dietary supplementation. Caution should be exercised in prescribing enteric-coated potassium tablets. Consult your veterinarian and see package insert for full information regarding contraindications, warnings, and precautions. For complete information, refer to the product's package insert.

For veterinary use only, consult a veterinarian before use. Not for use in humans. Keep out of reach of children.

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

For more safety information, please refer to the Furosemide Tablets full [Prescribing Information](#).

Approved by FDA under ANADA # 200-759

About ZyVet Animal Health

Founded in 2019 and headquartered in Pennington, New Jersey, **ZyVet® Animal Health** is dedicated to providing high-quality generic medications for companion animals. A wholly-owned division of **Zydus Lifesciences**, one of the world's largest generics manufacturers, ZyVet leverages a global legacy of pharmaceutical excellence to serve the veterinary community with accessible, reliable treatment options. Visit ZyVetUSA.com to learn more about ZyVet's expanding portfolio of affordable solutions for today's veterinary practice.

About Zydus Lifesciences Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 28,000 people worldwide, including 1,500 scientists engaged in R&D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. For more details visit www.zyduslife.com

Contact Information

Courtney Carney, Marketing & Communications

ccarney@zydususa.com

Phone: (682) 552-4520